Laboratory Of America
As on 02 Jul, 2025 | 01:29 IST
| Open | 261.62 |
| Previous Close | 262.51 |
| Beta | 0.40 |
| High | 265.72 |
| Low | 261.03 |
| TTM EPS See historical trend | 14.73(+4.03% YoY) |
| 52 Week High | 265.72 |
| 52 Week Low | 199.12 |
| TTM PE See historical trend | 17.94(High PE) |
| Mkt. Cap ($ Billion) | 22.22 |
| Dividend Yield | 1.24 |
Advanced Chart
*Delayed by 20 seconds.
MC Technicals
| Days | |
|---|---|
| 5 | 260.57 |
| 10 | 260.95 |
| 20 | 259.11 |
| 50 | 248.42 |
| 100 | 244.21 |
| 200 | 237.18 |
Returns
| 1 Week | 1.20% | |
| 1 Month | 6.16% | |
| 3 Months | 15.03% | |
| YTD | 15.34% | |
| 1 Year | 29.93% | |
| 3 Years | 12.74% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| UnitedHealth | 365.61 | 0.31 | 336.86 | 14.48 | 25.24 | 2.73 | 624.01/234.61 | 8.47 | Very Bearish |
| Thermo Fisher Scientific | 557.99 | 2.60 | 212.88 | 25.50 | 21.89 | 0.41 | 610.77/385.72 | 16.30 | Very Bullish |
| Danaher | 221.14 | 6.12 | 159.51 | 29.33 | 7.53 | 0.59 | 268.40/171.26 | 14.30 | Neutral |
| CVS Health | 83.04 | 0.68 | 104.49 | 13.10 | 6.34 | 3.86 | 83.52/43.56 | 10.77 | Bearish |
| HCA | 431.59 | -0.36 | 103.05 | 17.21 | 22.64 | 0.83 | 417.11/290.13 | 2.06 | Very Bullish |
Market news
- Wall Street ends higher as investors digest Trump trade commentsOctober 18, 2025 8:37 AM
- Wall Street sells off as Trump hits China with more tariffsOctober 11, 2025 8:32 AM
- Dow, S&P 500 manage record closing highs; Nasdaq falls in volatile sessionOctober 4, 2025 9:34 AM
- Wall Street closes higher, boosted by healthcare as investors shrug off jobs data, US shutdownOctober 2, 2025 8:05 AM
About the company
Laboratory Corporation of America Holdings is a life sciences company that provides clinical laboratory and end-to-end drug development services. The Company’s business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The Company also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The Company serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers.